Navigation Links
ENMD in Medical News

EntreMed Reports Second Quarter 2009 Financial Results

... ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six...

EntreMed Reports First Quarter 2009 Financial Results

... ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial res...

EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results

... ROCKVILLE, Md., March 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for t...

EntreMed Focuses on Development of ENMD-2076

...agement Realigned to Provide Full Support for Clinical Activities ROCKVILLE, Md., Dec. 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company announced today plans to focus the Company's resources on its most promising near-term product candidate, E...

EntreMed Reports Clinical Program Progress and Company Update

... ROCKVILLE, Md., Nov. 12, /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, reported corporate and clini...

EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference

... ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program

... Additional Resources to Accelerate ENMD-2076 Partnering Efforts ROCKVILLE, Md., Aug. 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed to Present at the BIO 2008 Annual International Convention

... ROCKVILLE, Md., June 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference

... ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

Dr. Ronald E. Cape to Retire from EntreMed Board of Directors

... ROCKVILLE, Md., April 7, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the retireme...
ENMD in Medical Technology

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

...ded Clinical Program Now Includes Solid and Hematological Malignancies ROCKVILLE, Md., June 1 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for i...

EntreMed Presents Initial Clinical Results for ENMD-2076

...ug Designation and Canadian CTA Accelerate ENMD-2076 Program Momentum ROCKVILLE, Md., Feb. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced recent devel...

EntreMed Receives New Patent for 2-Methoxyestradiol Analogs

... Patent Covers Compositions and Methods ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the issuance...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

... Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting

...pounds Demonstrate Potent Antitumor Activity in a Variety of Tumor Types ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting

...ral Presentation During the "New Drugs on the Horizon 2" Special Session ROCKVILLE, Md., April 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced it will pres...

EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

...elective Kinase Inhibitor Phase 1 Trial in Advanced Cancer Patients ROCKVILLE, Md., April 9, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Commences Continuous Dosing Clinical Trial For MKC-1

... Phase 1 Study to be Conducted in Advanced Cancer Patients ROCKVILLE, Md., April 2, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers

... Multi-Center Clinical Trial to be Conducted in Canada ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the commence...

EntreMed to Present at The New York Society of Security Analysts Industry Conference

... ROCKVILLE, Md., Dec. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....
ENMD in Biological Technology

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

...nical Program Adds Leukemia Clinical Study and Orphan Drug Designation ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for three of its clinical...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

... ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed to Present at the New York Society of Security Analysts Industry Conference

... ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Compa...

EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial

... Phase 2 Randomized Study Under Consideration ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Reports Third Quarter 2008 Financial Results

... ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for t...

Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models

... ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publicat...

EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model

... ROCKVILLE, Md., Oct. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed to Present at BioPartnering Europe Conference

... ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H...

EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market

... ROCKVILLE, Md., Oct. 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Reports Second Quarter 2008 Financial Results

... EntreMed to Conduct Update Call on Tuesday, August 12, 2008 ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial res...
Other Tags
(Date:5/24/2015)... CA (PRWEB) May 24, 2015 ProPin ... in Final Cut Pro X. Utilize ProPin to pin point ... a given scene. , ProPin allows users to choose ... customizable in FCPX. With on-screen controls, video editors can easily ... users to pin and mark with absolute ease. , Using ProPin ...
(Date:5/23/2015)... On Saturday, May 23, 2015, over 100 volunteers are ... City exactly five years to the day after the disastrous ... large fire tore through the Branches United Methodist Church and ... middle of the night as neighbors, staff and Branches' children ... though it is suspected that the fire began accidentally. Branches ...
(Date:5/23/2015)... Parker, CO (PRWEB) May 23, 2015 On ... participated in MuckFest. The event was a 5k mud obstacle ... affects more than 2 million people worldwide, and the reason ... our community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. ... National Multiple Sclerosis Society.” , The event was not only ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Injury lawyer Steven ... has been passed by the Maryland legislature but which has ... Maryland General Assembly passed HB 449 with overwhelming ... has not signed it into law. This bill ensures that ... is growing that demonstrates the danger of fracking to our ...
(Date:5/22/2015)... May 22, 2015 River Valley Health ... Johnson, the health system’s Chief Financial Officer (CFO), will ... has served as the company CFO since 2011. , ... be joining the health system as CFO. Wesley will ... basis, while the Board of Trustees conducts a formal ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
Other Contents